PDF(Pubmed)
Abstract：
BACKGROUND: In recent years, immune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy across diverse malignancies. Notably, in patients with advanced gastric cancer, the use of programmed death 1 (PD-1) blockade has significantly prolonged overall survival, marking a pivotal advancement comparable to the impact of Herceptin over the past two decades. While the therapeutic benefits of ICIs are evident, the increasing use of immunotherapy has led to an increase in immune-related adverse events.
METHODS: This article presents the case of a patient with advanced gastric cancer and chronic plaque psoriasis. Following sintilimab therapy, the patient developed severe rashes accompanied by cytokine release syndrome (CRS). Fortunately, effective management was achieved through the administration of glucocorticoid, tocilizumab, and acitretin, which resulted in favorable outcomes.
CONCLUSIONS: Glucocorticoid and tocilizumab therapy was effective in managing CRS after PD-1 blockade therapy for gastric cancer in a patient with chronic plaque psoriasis.
METHODS: This article presents the case of a patient with advanced gastric cancer and chronic plaque psoriasis. Following sintilimab therapy, the patient developed severe rashes accompanied by cytokine release syndrome (CRS). Fortunately, effective management was achieved through the administration of glucocorticoid, tocilizumab, and acitretin, which resulted in favorable outcomes.
CONCLUSIONS: Glucocorticoid and tocilizumab therapy was effective in managing CRS after PD-1 blockade therapy for gastric cancer in a patient with chronic plaque psoriasis.
摘要：
背景：近年来，免疫检查点抑制剂(ICIs)在各种恶性肿瘤中表现出显著的疗效.值得注意的是,在晚期胃癌患者中，使用程序性死亡1（PD-1）阻断显著延长总生存期，标志着与赫赛汀在过去二十年中的影响相当的关键进步。虽然ICIs的治疗益处是显而易见的，越来越多地使用免疫治疗导致免疫相关不良事件增加.
方法：本文介绍一例进展期胃癌和慢性斑块状银屑病患者。在辛替利玛治疗之后，患者出现严重皮疹并伴有细胞因子释放综合征(CRS).幸运的是,通过糖皮质激素的管理实现了有效的管理，托珠单抗,和阿西汀,这导致了有利的结果。
结论：糖皮质激素和托珠单抗治疗可有效控制慢性斑块型银屑病患者胃癌PD-1阻断治疗后的CRS。
方法：本文介绍一例进展期胃癌和慢性斑块状银屑病患者。在辛替利玛治疗之后，患者出现严重皮疹并伴有细胞因子释放综合征(CRS).幸运的是,通过糖皮质激素的管理实现了有效的管理，托珠单抗,和阿西汀,这导致了有利的结果。
结论：糖皮质激素和托珠单抗治疗可有效控制慢性斑块型银屑病患者胃癌PD-1阻断治疗后的CRS。
